4-azidosalicylic acid-phosphatidylserine: structure given in first source; RN given is for 125I-labeled cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6449857 |
| MeSH ID | M0191704 |
| Synonym |
|---|
| 124155-78-8 |
| asa-ps |
| l-serine, n-(4-azido-2-hydroxy-3-(iodo-125i)benzoyl)-, 3-(2-((1-oxo-9-octadecenyl)oxy)-3-((1-oxooctadecyl)oxy)propyl hydrogen phosphate), (r-(z))- |
| 4-azidosalicylic acid-phosphatidylserine |
| (2s)-2-[(4-azido-2-hydroxy-3-iodobenzoyl)amino]-3-[hydroxy-[(2r)-3-octadecanoyloxy-2-[(z)-octadec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 6 (85.71) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.25) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 1 (12.50%) | 0.25% |
| Other | 7 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||